x

Posted 05 February, 2024

Inspire Medical Systems, Inc. appointed new CEO

CEO Change detected for ticker NYSE:INSP in a 8-K filed on 05 February, 2024.


  On February 5, 2024, the Company announced that the Board has appointed Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, succeeding Ms. Nelson, to be effective at the conclusion of the 2024 Annual Meeting.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Inspire Medical Systems, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.
Market Cap
$5.87B
View Company Details
Inspire Medical Systems, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b) On January 30, 2024, Marilyn Carlson Nelson, Chair of the Board of Directors (the "Board") of Inspire Medical Systems, Inc. (the "Company"), notified the Company of her decision to retire from the Board and not stand for re-election at the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting") scheduled to occur on May 2, 2024. Ms. Nelson's retirement will become effective at the conclusion of the 2024 Annual Meeting. Ms. Nelson's decision to retire and not stand for re-election was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

On February 5, 2024, the Company announced that the Board has appointed Chief Executive Officer Timothy P. Herbert to the additional role of Board Chair, succeeding Ms. Nelson, to be effective at the conclusion of the 2024 Annual Meeting. Mr. Herbert's decades of expertise in the medical device industry as well as his deep understanding of the business that he founded make him uniquely qualified to effectively manage the business, execute on the Company's strategic priorities and lead the Board.

The Board has appointed Gary Ellis to the role of Lead Independent Director to be effective at the conclusion of the 2024 Annual Meeting. Mr. Ellis will continue to serve in his role as the Chair of the Company's Nominating and Corporate Governance Committee.